Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of IONIS-FXIRx in hemodialysis patients with end-stage renal disease
NL-OMON46462Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jul 2018
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of fesomersen, sponsored by Ionis Pharmaceuticals. Started Jul 2018; status: completed.
02
Drugs
fesomersen
Beyond the preview
Go deeper on NL-OMON46462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46462.